Literature DB >> 15735661

Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.

J-H Lee1, S-J Choi, J-H Lee1, Y-S Lee, M Seol, S-G Ryu, J-S Lee, W-K Kim, K-H Lee.   

Abstract

Using non-total body irradiation (TBI) containing preparative regimens, 13 patients with severe aplastic anemia (SAA) were transplanted from an alternative donor in a single institute. In total, 12 donors were unrelated volunteers and one was an HLA one-locus mismatched sibling. Median time from diagnosis of SAA to bone marrow transplantation (BMT) was 10.1 months (range, 1.6-180.1). Nine patients had received immunosuppressive treatment with ATG before BMT, while four had not. Preparative regimens consisted of cyclophosphamide plus ATG in nine patients, cyclophosphamide plus fludarabine in two patients, and cyclophosphamide plus fludarabine plus ATG in two patients. All patients received non-T-cell depleted bone marrow from the donor. Cyclosporine plus methotrexate were given for GVHD prophylaxis. All patients engrafted on a median of day 21 (range, 15-27). Grade III-IV acute GVHD developed in three (23%) of 13 patients and extensive chronic GVHD in four (31%) of 12 evaluable patients. With a median follow-up duration of 1138 days (range, 118-1553), 10 patients are alive with durable engraftment showing 74.6% (95% confidence interval, 49.5-99.7%) of survival rate. Cause of the deaths was CNS bleeding in one and chronic GVHD in two. In conclusion, non-TBI containing preparative regimen could ensure durable engraftment in alternative donor BMT for SAA and showed promising results.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15735661     DOI: 10.1038/sj.bmt.1704880

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.

Authors:  Chayamon Takpradit; Susan E Prockop; Nancy A Kernan; Andromachi Scaradavou; Kevin Curran; Julianne Ruggiero; Nicole Zakak; Richard J O'Reilly; Farid Boulad
Journal:  J Pediatr Hematol Oncol       Date:  2018-05       Impact factor: 1.289

Review 2.  Current concepts in the pathophysiology and treatment of aplastic anemia.

Authors:  Neal S Young; Rodrigo T Calado; Phillip Scheinberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

3.  Favorable preliminary results using TLI/ATG-based immunomodulatory conditioning for matched unrelated donor allogeneic hematopoietic stem cell transplantation in pediatric severe aplastic anemia.

Authors:  Asha Pillai; Christine Hartford; Chong Wang; Deqing Pei; Jie Yang; Ashok Srinivasan; Brandon Triplett; Mari Dallas; Wing Leung
Journal:  Pediatr Transplant       Date:  2011-07-15

4.  Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study.

Authors:  Paolo Anderlini; Juan Wu; Iris Gersten; Marian Ewell; Jakob Tolar; Joseph H Antin; Roberta Adams; Sally Arai; Gretchen Eames; Mitchell E Horwitz; John McCarty; Ryotaro Nakamura; Michael A Pulsipher; Scott Rowley; Eric Leifer; Shelly L Carter; Nancy L DiFronzo; Mary M Horowitz; Dennis Confer; H Joachim Deeg; Mary Eapen
Journal:  Lancet Haematol       Date:  2015-09-02       Impact factor: 18.959

5.  Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.

Authors:  Jakub Tolar; H Joachim Deeg; Sally Arai; Mitchell Horwitz; Joseph H Antin; John M McCarty; Roberta H Adams; Marian Ewell; Eric S Leifer; Iris D Gersten; Shelly L Carter; Mary M Horowitz; Ryotaro Nakamura; Michael A Pulsipher; Nancy L Difronzo; Dennis L Confer; Mary Eapen; Paolo Anderlini
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-27       Impact factor: 5.742

6.  Fludarabine, cyclophosphamide, and antithymocyte globulin for matched related and unrelated allogeneic stem cell transplant in severe aplastic anemia.

Authors:  Paolo Anderlini; Sandra A Acholonu; Grace-Julia Okoroji; Roland E Bassett; Elizabeth J Shpall; Muzaffar H Qazilbash; Uday R Popat; Laura L Worth; Sergio A Giralt; Richard E Champlin
Journal:  Leuk Lymphoma       Date:  2010-10-12

7.  Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Authors:  J C Marsh; R M Pearce; M B C Koh; Z Lim; A Pagliuca; G J Mufti; J Perry; J A Snowden; A J Vora; R T Wynn; N Russell; B Gibson; M Gilleece; D Milligan; P Veys; S Samarasinghe; M McMullin; K Kirkland; G Cook
Journal:  Bone Marrow Transplant       Date:  2013-08-05       Impact factor: 5.483

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.